Company Overview of CareDx, Inc
CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics. The Post-Transplant Diagnostics segment develops and provides a diagnostic surveillance testing solution for heart and kidney transplant recipients. It offers AlloMap, a heart transplant molecular test; and AlloSure, a donor-derived cell free DNA test initially used for kidney transplant patients. The Pre-Transplant Diagnostics segment develops, manufactures, markets, and sells products tha...
3260 Bayshore Boulevard
Brisbane, CA 94005
Founded in 1998
Key Executives for CareDx, Inc
Chief Operating Officer
Total Annual Compensation: $325.0K
Compensation as of Fiscal Year 2016.
CareDx, Inc Key Developments
CareDx, Inc Presents at American Transplant Congress, Jun-05-2018 04:00 PM
May 24 18
CareDx, Inc Presents at American Transplant Congress, Jun-05-2018 04:00 PM. Venue: Sheraton Seattle Hotel, Seattle, Washington, United States. Speakers: Peter Maag, President, CEO & Director.
CareDx, Inc Presents at 15th Annual Craig-Hallum Institutional Investor Conference, May-30-2018 08:00 AM
May 17 18
CareDx, Inc Presents at 15th Annual Craig-Hallum Institutional Investor Conference, May-30-2018 08:00 AM. Venue: Renaissance Minneapolis Hotel, The Depot, Minneapolis, Minnesota, United States.
CareDx, Inc Announces Preliminary Earnings Results for the First Quarter Ended March 31, 2018; Provides Revenue Guidance for the Full Year 2018
May 10 18
CareDx Inc. announced preliminary earnings results for the first quarter ended March 31, 2018. For the quarter, the company reported revenue for the three months ended March 31, 2018 was $14.1 million, an increase of 21% compared with $11.6 million in the first quarter of 2017. Net loss was $9.0 million compared to a net loss of $5.6 million in the same period of 2017. Basic and diluted net loss per share was $0.30 in the first quarter of 2018, compared to basic and diluted net loss per share of $0.26 in the first quarter of 2017. Loss from operations was $5,235,000 compared to $8,544,000 a year ago. Loss before income taxes was $9,418,000 compared to $5,892,000 a year ago. Non-GAAP net loss was $4,016,000 compared to $6,663,000 a year ago. Non-GAAP basic and diluted net loss per share attributable to the company was $0.14 compared to $0.31 a year ago. Net cash used in operating activities was $4.5 million. Net cash used in operating activities in the first quarter 2018 was $4.5 million.
For the full year 2018, company expects revenue to be in the range of $64 million to $66 million, with non-GAAP EBITDA profitability expected during the second half of the year. This guidance includes the anticipated contribution from the partnership agreement with Illumina to exclusively sell its Next Generation Sequencing transplantation products. Each of the components of CareDx’s guidance is an estimate only and actual performance could differ. The company partnership with Illumina, the positive Medicare price increase from AlloMap and the growth of the company pre-transplant revenues from Olerup QTYPE, the company continue to anticipate reaching non-GAAP EBITDA profitability during the second half of 2018.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 17, 2018
March 1, 2018